Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension

Journal of Hypertension

Volumn 25, Issue 3, 2007, Pages 577-583

  Zieman, Susan J ^a,b   Melenovsky, Vojtech ^a   Clattenburg, Lia ^a   Corretti, Mary C ^a   Capriotti, Anne ^a   Gerstenblith, Gary ^a   Kass, David A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Advanced glycation endproducts; Aging; Arterial stiffness; Clinical trial; Endothelial dysfunction; Flow mediated dilation; Isolated systolic hypertension

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CELL ADHESION MOLECULE; COLLAGEN; COLLAGEN TYPE 1; DIURETIC AGENT; GELATINASE B; NITRATE; NITRITE; PADGEM PROTEIN; PLACEBO;

ADULT; AGED; ARTERY COMPLIANCE; ARTICLE; BRACHIAL ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS LINKING; DIASTOLIC BLOOD PRESSURE; DOPPLER ECHOGRAPHY; DRUG FATALITY; ENDOTHELIUM; FEMALE; HEART RATE; HUMAN; MALE; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYSTOLIC HYPERTENSION; TONOMETRY;

EID: 33846849277     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328013e7dd     Document Type: Article

References (49)

1. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a "set up" for vascular disease. Circulation 2003; 107:139-146.
2. Gerhard M, Roddy M, Creager S, Creager M. Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans. Hypertension 1996; 27:849-853.
3. Blacher J, Staessen J, Girerd X, Gasowski J, Thijs L, Liu L, et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med 2000; 160:1085-1089.
4. Franklin SS, Larson MG, Khan SA, Wong ND, Leip F, Kannel WB, Levy D. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103:1245- 1249.
5. Oliver JJ, Webb DJ. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. Arterioscler Thromb Vasc Biol 2003; 23:554-566.
6. Quyyumi A. Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am J Med 1998; 105:32S-39S.
7. Taddei S, Virdis A, Mattei P, Ghiadoni L, Gennari A, Fasolo CB, et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 1995; 91:1981-1987.
8. Bishop JE, Lindahl G. Regulation of cardiovascular collagen synthesis by mechanical load. Cardiovasc Res 1999; 42:27-44.
9. Peng X, Haldar S, Deshpande S, Irani K, Kass DA. Wall stiffness suppresses Akt/eNOS and cytoprotection in pulse-perfused endothelium. Hypertension 2003; 41:378-381.
10. Li M, Chiou KR, Bugayenko A, Irani K, Kass DA. Reduced wall compliance suppresses Akt-dependent apoptosis protection stimulated by pulse perfusion. Circ Res 2005; 97:587.
11. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004; 63:582-592.
12. Lee A, Cerami A. Role of glycation in aging. Ann NY Acad Sci 1992; 663:63-70.
13. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318:1315-1321.
14. Zieman SJ, Kass DA. Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease. Drugs 2004; 64:459-470.
15. Bucala R, Tracey K, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87:432-438.
16. Chen J, Brodsky SV, Goligorsky DM, Hampel DJ, Li H, Gross SS, Goligorsky MS. Glycated collagen I induces premature senescence-like phenotypic changes in endothelial cells. Circ Res 2002; 90:1290-1298.
17. Bucala R, Mitchell R, Arnold K, Innerarity T, Vlassara H, Cerami A. Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor. J Biol Chem 1995; 270:10828-10832.
18. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004; 63:582-592.
19. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells. Kidney Int 2003; 63:464-473.
20. Vaitkevicius P, Lane M, Spurgeon H, Ingram D, Roth G, Egan J, et al. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Natl Acad Sci U S A 2001; 98:1171-1175.
21. Kass D, Shapiro E, Kawaguchi M, Capriotti A, Scuteri A, deGroof R, Lakatta E. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001; 104:1464-1470.
22. Corretti M, Anderson T, Benjamin E, Celermajer D, Charbonneau F, Creager M, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39:257-265.
23. Peng X, Recchia F, Byrne B, Wittstein I, Ziegelstein R, Kass D. In vitro system to study realistic pulsatile flow and stretch signaling in cultured vascular cells. Am J Physiol Cell Physiol 2000; 279:C797-C805.
24. Liang YL, Teede H, Kotsopoulos D, Shiel L, Cameron JD, Dart AM, McGrath BP. Non-invasive measurements of arterial structure and function: repeatability, interrelationships and trial sample size. Clin Sci (Lond) 1998; 95:669-679.
25. Chen CH, Ting CT, Nussbacher A, Nevo E, Kass DA, Pak P, et al. Validation of carotid artery tonometry as a means of estimating augmentation index of ascending aortic pressure. Hypertension 1996; 27:168-175.
26. Nichols W, O'Rourke M, editors. Properties of the arterial wall: practice. In: McDonald's blood flow in arteries. Theoretical, experimental and clinical principles, 4th ed. London, UK: Edward Arnold; 1998. pp. 73-97.
27. O'Rourke MF, Staessen JA, Vlachopoulos C, Duprez D, Plante GE. Clinical applications of arterial stiffness: definitions and reference values. Am J Hypertens 2002; 15:426-444.
28. Fassbach M, Schwartzkopff B. Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction. Z Kardiol 2005; 94:328-335.
29. Querejeta R, Lopez B, Gonzalez A, Sanchez E, Larman M, Martinez Ubago JL, Diez J. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 2004; 110:1263-1268.
30. Rajzer M, Klocek M, Kawecka-Jaszcz K. Effect of amlodipine, quinapril, and losartan on pulse wave velocity and plasma collagen markers in patients with mild-to-moderate arterial hypertension. Am J Hypertens 2003; 16:439-444.
31. Lopez B, Querejeta R, Varo N, Gonzalez A, Larman M, Martinez Ubago JL, Diez J. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001; 104:286-291.
32. Basta G, Lazzerini G, Del Turco S, Ratto GM, Schmidt AM, De Caterina R. At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products. Arterioscler Thromb Vasc Biol 2005; 25:1401-1407.
33. Bailey AJ. Molecular mechanisms of ageing in connective tissues. Mech Ageing Dev 2001; 122:735-755.
34. Verzijl N, DeGroot J, Thorpe SR, Bank RA, Shaw JN, Lyons TJ, et al. Effect of collagen turnover on the accumulation of advanced glycation end products. J Biol Chem 2000; 275:39027-39031.
35. Chirinos JA, Zambrano JP, Chakko S, Veerani A, Schob A, Willens HJ, et al. Aortic pressure augmentation predicts adverse cardiovascular events in patients with established coronary artery disease. Hypertension 2005; 45:980-985.
36. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340:115-126.
37. Laviades C, Varo N, Diez J. Transforming growth factor beta in hypertensives with cardiorenal damage. Hypertension 2000; 36:517-522.
38. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 2001; 38:581-587.
39. Tsuruda T, Costello-Boerrigter LC, Burnett JC Jr. Matrix metalloproteinases: pathways of induction by bioactive molecules. Heart Fail Rev 2004; 9:53-61.
40. Saura M, Zaragoza C, Herranz B, Griera M, Diez-Marques L, Rodriguez-Puyol D, Rodriguez-Puyol M. Nitric oxide regulates transforming growth factor-beta signaling in endothelial cells. Circ Res 2005; 97:1115-1123.
41. Stern D, Du YS, Fang YS, Marie SA. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev 2002; 54:1615-1625.
42. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269:9889-9897.
43. Throckmorton DC, Brogden AP, Min B, Rasmussen H, Kashgarian M. PDGF and TGF-beta mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int 1995; 48:111-117.
44. Zhou Z, Wang K, Penn MS, Marso SP, Lauer MA, Forudi F, et al. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation 2003; 107:2238-2243.
45. Kislinger T, Tanji N, Wendt T, Qu W, Lu Y, Ferran LJ Jr, et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2001; 21:905-910.
46. Wendt T, Harja E, Bucciarelli L, Qu W, Lu Y, Rong LL, et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 2005; 185:70-77.
47. Xu B, Ji Y, Yao K, Cao YX, Ferro A. Inhibition of human endothelial cell nitric oxide synthesis by advanced glycation endproducts but not glucose: relevance to diabetes. Clin Sci 2005; 109:439-446.
48. Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci U S A 1992; 89:12043-12047.
49. Bakris GL, Bank AJ, Kass DA, Neutel JM, Preston RA, Oparil S. Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. Am J Hypertens 2004; 17:23S-30S.